A 2-PART, PHASE 1, OPEN LABEL STUDY WITH A 4-PERIOD, 4-SEQUENCE, CROSSOVER DESIGN IN COHORT 1 AND A 2-PERIOD, 2-SEQUENCE CROSSOVER DESIGN IN COHORT 2 TO COMPARE THE SINGLE DOSE PHARMACOKINETICS OF FIVE DIFFERENT FORMULATIONS OF PF-06882961 ADMINISTERED ORALLY TO OTHERWISE HEALTHY ADULT PARTICIPANTS WHO ARE OVERWEIGHT OR HAVE OBESITY
Latest Information Update: 11 Apr 2022
At a glance
- Drugs Danuglipron (Primary)
- Indications Obesity
- Focus Pharmacokinetics
- Sponsors Pfizer
- 28 Jul 2021 Status changed from recruiting to completed.
- 04 Mar 2021 Planned number of patients changed from 16 to 32.
- 04 Mar 2021 Planned End Date changed from 18 Feb 2021 to 28 May 2021.